Returns Breakdown
| Return On Tangible Assets | (0.3) | |
| Return On Capital Employed | (0.18) | |
| Return On Assets | (0.13) | |
| Return On Equity | (0.21) |
Are Accolade (USA Stocks:ACCD) shareholders starting to hold back?
 | By Ellen Johnson | Macroaxis Story |
Accolade (NASDAQ: ACCD) has recently seen a rise of over 5%, even as the broader market experiences a downturn. This uptick could be attributed to its position within the Health Care Technology sector, which often garners investor interest during volatile times. Despite a challenging earnings landscape, with an EPS estimate for the current year showing a loss of 1.21, the stock's potential upside of 8.4% suggests room for growth. With a short ratio of 5.34, there is a moderate level of short interest, indicating that some investors are betting against the stock, but the overall sentiment remains cautiously optimistic.
Main Ideas
Accolade's beta is 2.6584, indicating it is more volatile than the market. This means that when the market rises, Accolade is likely to see even bigger gains. Conversely, if the market falls, Accolade could experience sharper losses. The beta helps investors gauge how Accolade's stock moves in relation to the market and assess its risk level. A high beta suggests more risk but also the potential for higher returns. If Accolade's stock closely follows the market, it doesn't significantly alter the risk or return profile of a portfolio.Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Vlad Skutelnik
In the world of investing, timing is everything, and Accolade (NASDAQ: ACCD) is making waves as it rises over 5% even as the broader market faces a downturn. This healthcare stock, trading on the NASDAQ, is capturing attention with its recent price movement. Despite a challenging fiscal landscape, with an EPS estimate for the current year showing a loss of 1.21, the stock is still gaining traction. Analysts are optimistic, with a strong buy consensus and a target price estimated at 14.77, suggesting significant upside potential from its current levels. As the fiscal year draws to a close in February, investors are keeping a close watch on Accolade's performance, intrigued by its resilience and future prospects. Currently, Accolade's Price-to-Book Ratio is anticipated to rise slightly based on recent years' data. This year, the Capital Expenditure to Depreciation ratio is expected to increase to 0.37, while the Enterprise Value might decrease to approximately $422.7 million. This analysis aims to evaluate Accolade as a potential investment for November. We'll explore why recent price trends hint at a possible rebound this month.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Accolade. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Predictive Modules for Accolade
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Accolade's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
How important is Accolade's Liquidity
Accolade financial leverage refers to using borrowed capital as a funding source to finance Accolade ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Accolade financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Accolade's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Accolade's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Accolade's total debt and its cash.
Accolade Gross Profit
Accolade Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Accolade previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Accolade Gross Profit growth over the last 10 years. Please check Accolade's gross profit and other fundamental indicators for more details.
Is Accolade valued correctly by the market?
Accolade shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Accolade's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Accolade's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.
In the world of investing, it's often said that "the trend is your friend," and Accolade (NASDAQ: ACCD) seems to be riding a positive wave, climbing over 5% even as the broader market experiences a pullback. This healthcare technology company, with a market capitalization of $317.63 million, has shown resilience despite its challenges. With a current ratio of 3.33X, Accolade demonstrates a strong ability to cover its short-term liabilities, which is a reassuring sign for investors. However, the company is still navigating financial hurdles, as indicated by its estimated loss of $1.21 per share for the current year. As the stock trades near its 52-week low of $3.35, the Wall Street target price of $8.17 suggests significant potential upside, making it a stock to watch for those willing to embrace some risk..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Accolade. Please refer to our Terms of Use for any information regarding our disclosure principles.